Skip to main content

Table 1 Clinical features of patients with symptomatic radiation necrosis

From: The roles of platelet-derived growth factors and their receptors in brain radiation necrosis

Pt. Age (y) Sex Original dis. Radiationa Resection area (lobe) Durationb Chemo
1 46 F SCC. XRT (60 Gy), BNCT (13.9 Gy-Eq) Temporal 7 MTX
2 78 M Sal. Duc. Ca. XRT (60 Gy), BNCT (13.9 Gy-Eq) Frontotemporal 20 -
3 18 M GBM XRT (IMRT) (74 Gy) Parietal 37 -
4 63 F GBM XRT (24 Gy), BNCT (13 Gy-Eq) Frontoparietal 4 -
5 34 M GBM XRT (24 Gy), BNCT (13 Gy-Eq) Frontal 6 -
6 56 F GBM Proton + XRT (total 90 Gy) Temporoparietal 10 ACNU
7 46 F Ade. Ca. XRT (30 Gy), SRS (55 Gy, 65 Gy) Frontal 32 Herceptin
  1. Pt, patient; y, year; F, female; M, male; Original dis, original disease; SCC, Squamous cell carcinoma; Sal. Duc. Ca, salivary ductal carcinoma; GBM, glioblastoma; Ade. Ca, adenocarcinoma; XRT, X-ray radiation treatment; IMRT ,intensity modulated radiation therapy; BNCT, boron neutron capture therapy; Proton, proton beam therapy; MTX, methotrexate; ACNU, nimustin; Herceptin, trastuzumab;
  2. aIn Pt. 1 and 2, the temporal lobe was included in the irradiation field and in Pt. 3, 4, 5, and 6, local radiation therapy was administered. Pt. 7 had received whole brain irradiation and received SRS twice. In BNCT, the presented dose is the peak point dose for the normal brain.
  3. bMonths between termination of the last radiotherapy and onset of symptoms caused by radiation necrosis.